Trevi Therapeutics, Inc. cotiza a 12.29 USD y tiene una capitalización bursátil de $1.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral ext…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.09 | $-0.06 |
| Estimado | $-0.13 | $-0.11 | $-0.07 | $-0.10 |
| Sorpresa | — | +0.0% | -28.6% | +40.0% |
| Métrica | TRVI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -23.3% | -40.4% | +17.1% |
| ROA | -22.1% | -32.0% | +9.9% |
| Current Ratio | 19.66 | 2.84 | +16.82 |
| Debt / Equity | — | 0.28 | — |